May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Bevacizumab and Ranibizumab Tachyphylaxis in the Treatment of Choroidal Neovascularization
Author Affiliations & Notes
  • J. L. Gasperini
    Ophthalmology, Retina, Doheny Retina Institute, USC, Los Angeles, California
  • A. Fawzi
    Ophthalmology, Retina, Doheny Retina Institute, USC, Los Angeles, California
  • L. Lam
    Ophthalmology, Retina, Doheny Retina Institute, USC, Los Angeles, California
  • L. Chong
    Ophthalmology, Retina, Doheny Retina Institute, USC, Los Angeles, California
  • D. Eliott
    Ophthalmology, Retina, Doheny Retina Institute, USC, Los Angeles, California
  • A. Walsh
    Ophthalmology, Retina, Doheny Retina Institute, USC, Los Angeles, California
  • S. Sadda
    Ophthalmology, Retina, Doheny Retina Institute, USC, Los Angeles, California
  • Footnotes
    Commercial Relationships  J.L. Gasperini, None; A. Fawzi, None; L. Lam, None; L. Chong, None; D. Eliott, None; A. Walsh, Topcon, P; S. Sadda, Topcon, P.
  • Footnotes
    Support  RPB
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 346. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. L. Gasperini, A. Fawzi, L. Lam, L. Chong, D. Eliott, A. Walsh, S. Sadda; Bevacizumab and Ranibizumab Tachyphylaxis in the Treatment of Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2008;49(13):346. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate patients with choroidal neovascularization(CNV) with poor initial morphologic response to ranibizumab or bevicizumab therapy, to determine if these patients respond after changing the treatment regimen to a different anti-vascular endothelial growth factor (VEGF) drug, bevacizumab or ranibizumab.

Methods: : Retrospective chart review of patients treated for CNV at the Doheny Eye Institute from September 2006 through November 2007 with both ranibizumab and bevacizumab. OCT features of exudation [subretinal fluid (SRF), pigment epithelial detachment (PED), and/or cystoid macular edema (CME)] were evaluated during the course of therapy. Lack of reduction or an increase in exudation was considered evidence of poor response.

Results: : 22 eyes of 23 patients were treated with both bevacizumab and ranibizumab for CNV. 6 of the 22 eyes were initially treated with bevacizumab. These eyes received on average 5 injections of bevacizumab prior to changing the treatment regimen to ranibizumab for non-responding SRF, PED, and/or CME. 2 of the 6 eyes were initially treated with bevacizumab for classic CNV and 4 eyes for an occult CNV with pigment epithelial detachment (PED). Of the 2 eyes with classic CNV, in one eye, SRF completely resolved after 4 ranibizumab injections, while the other eye is still undergoing treatment for improving but persistent SRF. All 4 eyes with occult CNV started to respond after 1 ranibizumab injection.17 of the 22 eyes were initially treated with ranibizumab. These eyes received on average 5 injections of ranibizumab prior to changing the treatment regimen to bevacizumab for poor response. On average, 3 injections of bevacizumab were administered. Of the 17 eyes initially treated with ranibizumab, 1 eye was treated for classic CNV and 16 eyes for occult CNV (14/16 eyes had PED). 3 eyes did not respond to the change to bevacizumab, while 9 eyes showed a response (reduction or resolution) after only 1 injection and 5 eyes after 2 injections.

Conclusions: : Patients with CNV that show a poor initial response to ranibizumab or bevacizumab therapy may yield a better response after switching to another anti-VEGF drug. Some patients require multiple injections to demonstrate a treatment response.

Keywords: age-related macular degeneration • vascular endothelial growth factor • retinal neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×